RB
Amphastar Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| BAQSIMI® (Glucagon Nasal Powder) | Severe Hypoglycemia (Very Low Blood Sugar) | Approved/Commercial |
| Iron Sucrose Injection, USP | Iron Deficiency Anemia in Chronic Kidney Disease | Approved/Commercial |
| Teriparatide Injection | Osteoporosis | Approved/Commercial |
| Primatene® MIST (Epinephrine Inhalation Aerosol) | Mild, Intermittent Asthma | Approved/Commercial |
| Albuterol Sulfate Inhalation Aerosol | Bronchospasm (Asthma, COPD) | Approved/Commercial |
| Biosimilars Pipeline | Various (e.g., Diabetes, Oncology) | Pre-clinical to Phase 3 |
| Complex Injectable Generics Pipeline | Various | ANDA Filed / Development |
Leadership Team at Amphastar Pharmaceuticals
JY
Jack Y. Zhang
Co-Founder, President, and Chief Executive Officer
WJ
William J. Peters
Chief Financial Officer
MZ
Mary Z. Luo
Co-Founder, Chairperson, and Chief Scientific Officer
MA
Michael A. Zasloff
Executive Vice President, General Counsel, and Secretary
RA
Richard A. Prins
Board Member
GJ
Gary J. Matus
Board Member